Phase 1 Study of Drug-Drug Interactions Between DWP16001, DWC202407, and DWC202408 in Healthy Adults

Launched by DAEWOONG PHARMACEUTICAL CO. LTD. · Oct 14, 2024

Keywords

ClinConnect Summary

This clinical trial is a Phase 1 study designed to investigate how three different drugs—DWP16001, DWC202407, and DWC202408—interact with each other in healthy adults. The goal is to understand how these drugs behave in the body when taken together. The study is not yet recruiting participants, but it plans to include healthy adult volunteers between the ages of 19 and 50 years who meet specific health criteria.

To be eligible for this study, participants should weigh between 50 to 90 kilograms and have a body mass index (BMI) that falls within a healthy range. Women who wish to participate must not be pregnant or breastfeeding, or they should have undergone certain surgical procedures that prevent pregnancy. Participants will be fully informed about the trial and must agree to take part voluntarily. If you choose to join, you can expect to learn more about the drugs and their effects, while contributing to important research that may help in future treatments.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Healthy adult volunteers aged 19 to 50 years at the time of screening.
• • 2. Individuals with a body weight between 50.0 kg and 90.0 kg and a Body Mass Index (BMI) between 18.5 kg/m² and 29.9 kg/m² at the time of screening.
• • 3. Female volunteers must be neither pregnant nor breastfeeding, or must be in a surgically sterile state (e.g., bilateral tubal occlusion, hysterectomy, bilateral salpingectomy, bilateral oophorectomy).
• • 4. Individuals who have been fully informed about the clinical trial, have fully understood the details, voluntarily decided to participate, and provided written consent to comply with the precautions.